Taiho Pharmaceutical has patented a method for treating various cancers using an HSP90 inhibitor with enhanced efficacy and reduced side effects. The method involves administering a specific compound in combination with other antitumor agents. GlobalData’s report on Taiho Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Taiho Pharmaceutical, was a key innovation area identified from patents.
Method for treating cancer using hsp90 inhibitor and other agents
See Also:
A recently granted patent (Publication Number: US11918562B2) discloses a method for treating various types of tumors, including epidermal cancer, malignant melanoma, multiple myeloma, acute myelocytic leukemia, large intestine cancer, lung cancer, gallbladder cancer, stomach cancer, and breast cancer. The method involves administering a specific compound, 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl}benzamide or its salt, along with other antitumor agents such as docetaxel, paclitaxel, cisplatin, and more. The patent specifies a defined molar ratio range between the compound and other antitumor agents for effective treatment.
Furthermore, the patent outlines the administration of the compound and other antitumor agents either simultaneously or separately to the patient. It also includes details about the types of salts that can be used for the compound, such as acid addition salts of inorganic or organic acids, salts of inorganic or organic bases, salts of basic amino acids, and ammonium salts. The molar ratio range between the compound and other antitumor agents is crucial for achieving the desired therapeutic effect, as specified in the patent claims.
To know more about GlobalData’s detailed insights on Taiho Pharmaceutical, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
